How many people take semaglutide — and what the numbers actually tell us

The myth: semaglutide is a niche medicine taken by a small group

The biggest misconception about semaglutide is that it remains specialist territory, something prescribed only in hospital clinics to a handful of patients. The reality is strikingly different. Novo Nordisk's 2024 annual results noted that Ozempic (semaglutide for type 2 diabetes) and Wegovy (semaglutide for weight management) together generated revenues exceeding $25 billion USD that year, driven by rapidly expanding patient numbers across North America, Europe and the UK. That is not a niche medicine. It is, by any measure, a mass-market prescription treatment.

Globally, analysts estimate that somewhere between 30 and 50 million people were actively taking a semaglutide product by the end of 2024, across both the diabetes and weight-management indications. Precise figures are hard to pin down because different countries count prescriptions differently, and the same molecule is sold under different brand names for different licensed uses. What is clear is that the scale of uptake is genuinely historic for a prescription-only injectable medicine.

In the UK specifically, NHS Business Services Authority data showed semaglutide prescriptions rising steeply from 2023 onwards. Much of that early growth reflected Ozempic prescriptions for type 2 diabetes; Wegovy for weight management was only licensed here in 2023 and NHS access has been gradual and tightly phased. The number of people in the UK taking semaglutide for weight loss (as opposed to diabetes) is still comparatively small but growing quickly, particularly through private routes. You can read more about who is currently on Wegovy in the UK and what the access picture looks like in practice.

How many people are actually on Wegovy for weight loss?

Separating semaglutide-for-weight-loss numbers from semaglutide-for-diabetes numbers is genuinely difficult, because Ozempic and Wegovy are the same molecule at different doses, and prescribing databases do not always distinguish the indication. What we can say with confidence: the STEP programme of clinical trials, which underpinned Wegovy's UK licence, involved thousands of participants across multiple studies. STEP 1 alone recruited 1,961 adults with obesity, establishing the weight-loss results that made the medicine's approval possible. Those trial populations were not small samples.

In the real world, Novo Nordisk has repeatedly stated that supply constraints (not demand) limited how many people could start Wegovy globally through 2023 and into 2024. That is an unusual position for a medicine to be in. Demand outstripped capacity to manufacture it. By 2025, supply had largely stabilised in the UK, and private prescribing volumes climbed accordingly. NICE's appraisal of semaglutide (TA875) recommended it for NHS use within specialist weight management services, subject to strict criteria, which has kept NHS numbers lower than many patients expected.

The picture varies a lot by route. Someone who qualifies for NHS treatment may wait months for a specialist appointment. Someone who goes private (through a regulated pharmacy with a GPhC-registered prescriber) can begin treatment far sooner, subject to clinical suitability. That difference in access speed is a large part of why private semaglutide prescribing has grown so fast.

Who keeps taking it, and who stops?

Raw prescription numbers tell only half the story. Real-world adherence data, including a widely cited 2023 analysis published in Obesity (the journal of The Obesity Society), found that a significant proportion of people starting GLP-1 medicines for weight loss had discontinued within 12 months. Reasons included gastrointestinal side effects, cost, and the challenge of sustaining a weekly injection long-term. This matters because the question of why Wegovy does not work for some people is partly about biology and partly about persistence.

NICE's recommendation for semaglutide under TA875 includes a review point: if less than 5% of body weight has been lost after six months at the maintenance dose, continuing treatment should be reconsidered. That built-in check is part of responsible prescribing, the medicine is not for everyone, and that is not a failure, it is how clinical oversight is supposed to work. The NHS semaglutide medicines page outlines what to expect during treatment and when to contact a clinician.

There is also a timing element worth knowing: many people research and start treatment around specific life moments, after the January reset, before a summer holiday, or when a pay rise makes the monthly cost more manageable. Prescribing data does show seasonal peaks. That is completely understandable. The clinical suitability question stays the same regardless of when you enquire.

For anyone curious about the mechanics of how semaglutide works, our semaglutide overview covers the pharmacology in plain language. And if you want to understand the Wegovy product specifically (doses, the pen, what the licence covers) our Wegovy page is a good place to start.

What rising use means if you are considering treatment

The fact that millions of people are now taking semaglutide tells you something useful: the safety and effectiveness data generated in trials has been substantially reinforced by real-world use at scale. Post-marketing surveillance, Yellow Card reporting in the UK, and ongoing pharmacovigilance have not thrown up safety signals that override the original licence. That is reassuring context. It does not mean the medicine suits everyone, or that it is risk-free, GI side effects are common, particularly early on, and pancreatitis, though infrequent, is a known serious risk that the MHRA has highlighted in its ongoing safety communications. These are prescription-only medicines for a reason.

For a fuller sense of what the treatment involves practically, the dosing schedule page explains the once-weekly injection routine. If you want to understand what the dose numbers actually refer to, this page on semaglutide units covers that clearly. The weight-loss treatment overview sets all the licensed options in context.

If you think semaglutide might be right for you, the starting point is always a clinical assessment. A prescriber looks at your full picture (BMI, medical history, current medications, and your goals) before any treatment is recommended. Check your eligibility through a free consultation with our GPhC-registered prescribers.